Comparative in vitro activity of fleroxacin, two other quinolones and three board-spectrum beta-lactams using the E-Test.
Standard
Comparative in vitro activity of fleroxacin, two other quinolones and three board-spectrum beta-lactams using the E-Test. / Sobottka, Ingo; Neumann, S; Laufs, R.
in: CHEMOTHERAPY, Jahrgang 40, Nr. 5, 5, 1994, S. 293-298.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Comparative in vitro activity of fleroxacin, two other quinolones and three board-spectrum beta-lactams using the E-Test.
AU - Sobottka, Ingo
AU - Neumann, S
AU - Laufs, R
PY - 1994
Y1 - 1994
N2 - The in vitro activity of fleroxacin was compared to that of ciprofloxacin, ofloxacin and three broad-spectrum beta-lactams against 159 clinical isolates using the E-Test. Fleroxacin, ciprofloxacin, and ofloxacin were all active against Enterobacteriaceae with 93, 98 and 94% susceptibility, respectively. For other gram-negative strains, 81% were susceptible to fleroxacin and ofloxacin and 98% to ciprofloxacin. With regard to gram-positive strains, 72% were susceptible to fleroxacin, 83% to ciprofloxacin and 78% to ofloxacin. The broad antibacterial activity suggests that fleroxacin may be an alternative in the treatment of various infections, particularly in light of its favorable pharmacokinetics.
AB - The in vitro activity of fleroxacin was compared to that of ciprofloxacin, ofloxacin and three broad-spectrum beta-lactams against 159 clinical isolates using the E-Test. Fleroxacin, ciprofloxacin, and ofloxacin were all active against Enterobacteriaceae with 93, 98 and 94% susceptibility, respectively. For other gram-negative strains, 81% were susceptible to fleroxacin and ofloxacin and 98% to ciprofloxacin. With regard to gram-positive strains, 72% were susceptible to fleroxacin, 83% to ciprofloxacin and 78% to ofloxacin. The broad antibacterial activity suggests that fleroxacin may be an alternative in the treatment of various infections, particularly in light of its favorable pharmacokinetics.
M3 - SCORING: Zeitschriftenaufsatz
VL - 40
SP - 293
EP - 298
JO - CHEMOTHERAPY
JF - CHEMOTHERAPY
SN - 0009-3157
IS - 5
M1 - 5
ER -
